An update on ocular involvement in mucopolysaccharidoses

Research output: Contribution to journalArticle

15 Citations (Scopus)

Abstract

PURPOSE OF REVIEW: The purpose of this review is to provide an update on ocular manifestations of mucopolysaccharidoses (MPS), to highlight diagnostic pitfalls in the evaluation of affected patients, and to briefly review etiopathogenesis, systemic manifestations, and therapeutic interventions in MPS. RECENT FINDINGS: Advances in hematopoietic stem cell transplantation and enzyme replacement therapy for MPS have led to decreased morbidity and increased life-span of patients. Besides other causes, visual impairment because of corneal opacification, retinal degeneration, and optic atrophy remains a common cause of disability in MPS. The application of a standard ophthalmic evaluation protocol may serve as an important diagnostic and disease monitoring tool in patients. SUMMARY: Diagnostic delays are not uncommon in patients with MPS. Given the early ocular involvement in MPS, ophthalmologists play a crucial role in early detection and follow-up of patients with MPS. Ophthalmic evaluation can be impeded by corneal opacification and patient cooperation. Altered corneal biomechanics confound intraocular pressure measurements. Recently developed therapies have made early detection increasingly important. Accurate diagnosis of specific MPS subtypes is of paramount importance for initiating appropriate therapy. Combined with advances in supportive care of ocular and systemic manifestations, the prognosis for patients with MPS has vastly improved.

Original languageEnglish
Pages (from-to)379-388
Number of pages10
JournalCurrent Opinion in Ophthalmology
Volume24
Issue number5
DOIs
Publication statusPublished - Sep 2013

Fingerprint

Mucopolysaccharidoses
Eye Manifestations
Enzyme Replacement Therapy
Optic Atrophy
Retinal Degeneration
Hematopoietic Stem Cell Transplantation
Vision Disorders
Patient Compliance
Intraocular Pressure
Biomechanical Phenomena
Therapeutics
Morbidity

Keywords

  • Corneal clouding
  • Enzyme replacement therapy
  • Glaucoma
  • Mucopolysaccharidoses
  • Optic atrophy
  • Retinal degeneration
  • Stem cell transplantation

ASJC Scopus subject areas

  • Ophthalmology

Cite this

An update on ocular involvement in mucopolysaccharidoses. / Ganesh, Anuradha; Bruwer, Zandre; Al-Thihli, Khalid.

In: Current Opinion in Ophthalmology, Vol. 24, No. 5, 09.2013, p. 379-388.

Research output: Contribution to journalArticle

@article{dea8d96857b842589850500f714042d6,
title = "An update on ocular involvement in mucopolysaccharidoses",
abstract = "PURPOSE OF REVIEW: The purpose of this review is to provide an update on ocular manifestations of mucopolysaccharidoses (MPS), to highlight diagnostic pitfalls in the evaluation of affected patients, and to briefly review etiopathogenesis, systemic manifestations, and therapeutic interventions in MPS. RECENT FINDINGS: Advances in hematopoietic stem cell transplantation and enzyme replacement therapy for MPS have led to decreased morbidity and increased life-span of patients. Besides other causes, visual impairment because of corneal opacification, retinal degeneration, and optic atrophy remains a common cause of disability in MPS. The application of a standard ophthalmic evaluation protocol may serve as an important diagnostic and disease monitoring tool in patients. SUMMARY: Diagnostic delays are not uncommon in patients with MPS. Given the early ocular involvement in MPS, ophthalmologists play a crucial role in early detection and follow-up of patients with MPS. Ophthalmic evaluation can be impeded by corneal opacification and patient cooperation. Altered corneal biomechanics confound intraocular pressure measurements. Recently developed therapies have made early detection increasingly important. Accurate diagnosis of specific MPS subtypes is of paramount importance for initiating appropriate therapy. Combined with advances in supportive care of ocular and systemic manifestations, the prognosis for patients with MPS has vastly improved.",
keywords = "Corneal clouding, Enzyme replacement therapy, Glaucoma, Mucopolysaccharidoses, Optic atrophy, Retinal degeneration, Stem cell transplantation",
author = "Anuradha Ganesh and Zandre Bruwer and Khalid Al-Thihli",
year = "2013",
month = "9",
doi = "10.1097/ICU.0b013e3283644ea1",
language = "English",
volume = "24",
pages = "379--388",
journal = "Current Opinion in Ophthalmology",
issn = "1040-8738",
publisher = "Lippincott Williams and Wilkins",
number = "5",

}

TY - JOUR

T1 - An update on ocular involvement in mucopolysaccharidoses

AU - Ganesh, Anuradha

AU - Bruwer, Zandre

AU - Al-Thihli, Khalid

PY - 2013/9

Y1 - 2013/9

N2 - PURPOSE OF REVIEW: The purpose of this review is to provide an update on ocular manifestations of mucopolysaccharidoses (MPS), to highlight diagnostic pitfalls in the evaluation of affected patients, and to briefly review etiopathogenesis, systemic manifestations, and therapeutic interventions in MPS. RECENT FINDINGS: Advances in hematopoietic stem cell transplantation and enzyme replacement therapy for MPS have led to decreased morbidity and increased life-span of patients. Besides other causes, visual impairment because of corneal opacification, retinal degeneration, and optic atrophy remains a common cause of disability in MPS. The application of a standard ophthalmic evaluation protocol may serve as an important diagnostic and disease monitoring tool in patients. SUMMARY: Diagnostic delays are not uncommon in patients with MPS. Given the early ocular involvement in MPS, ophthalmologists play a crucial role in early detection and follow-up of patients with MPS. Ophthalmic evaluation can be impeded by corneal opacification and patient cooperation. Altered corneal biomechanics confound intraocular pressure measurements. Recently developed therapies have made early detection increasingly important. Accurate diagnosis of specific MPS subtypes is of paramount importance for initiating appropriate therapy. Combined with advances in supportive care of ocular and systemic manifestations, the prognosis for patients with MPS has vastly improved.

AB - PURPOSE OF REVIEW: The purpose of this review is to provide an update on ocular manifestations of mucopolysaccharidoses (MPS), to highlight diagnostic pitfalls in the evaluation of affected patients, and to briefly review etiopathogenesis, systemic manifestations, and therapeutic interventions in MPS. RECENT FINDINGS: Advances in hematopoietic stem cell transplantation and enzyme replacement therapy for MPS have led to decreased morbidity and increased life-span of patients. Besides other causes, visual impairment because of corneal opacification, retinal degeneration, and optic atrophy remains a common cause of disability in MPS. The application of a standard ophthalmic evaluation protocol may serve as an important diagnostic and disease monitoring tool in patients. SUMMARY: Diagnostic delays are not uncommon in patients with MPS. Given the early ocular involvement in MPS, ophthalmologists play a crucial role in early detection and follow-up of patients with MPS. Ophthalmic evaluation can be impeded by corneal opacification and patient cooperation. Altered corneal biomechanics confound intraocular pressure measurements. Recently developed therapies have made early detection increasingly important. Accurate diagnosis of specific MPS subtypes is of paramount importance for initiating appropriate therapy. Combined with advances in supportive care of ocular and systemic manifestations, the prognosis for patients with MPS has vastly improved.

KW - Corneal clouding

KW - Enzyme replacement therapy

KW - Glaucoma

KW - Mucopolysaccharidoses

KW - Optic atrophy

KW - Retinal degeneration

KW - Stem cell transplantation

UR - http://www.scopus.com/inward/record.url?scp=84883459785&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84883459785&partnerID=8YFLogxK

U2 - 10.1097/ICU.0b013e3283644ea1

DO - 10.1097/ICU.0b013e3283644ea1

M3 - Article

VL - 24

SP - 379

EP - 388

JO - Current Opinion in Ophthalmology

JF - Current Opinion in Ophthalmology

SN - 1040-8738

IS - 5

ER -